Mesoblast Limited (LWB) - Total Assets
Based on the latest financial reports, Mesoblast Limited (LWB) holds total assets worth €782.31 Million EUR (≈ $914.60 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Mesoblast Limited (LWB) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Mesoblast Limited - Total Assets Trend (2014–2025)
This chart illustrates how Mesoblast Limited's total assets have evolved over time, based on quarterly financial data. See Mesoblast Limited net assets for net asset value and shareholders' equity analysis.
Mesoblast Limited - Asset Composition Analysis
Current Asset Composition (June 2025)
Mesoblast Limited's total assets of €782.31 Million consist of 26.0% current assets and 74.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 20.5% |
| Accounts Receivable | €13.91 Million | 1.8% |
| Inventory | €22.25 Million | 2.8% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €437.37 Million | 55.7% |
| Goodwill | €134.45 Million | 17.1% |
Asset Composition Trend (2014–2025)
This chart illustrates how Mesoblast Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Mesoblast Limited (LWB) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mesoblast Limited's current assets represent 26.0% of total assets in 2025, an increase from 22.7% in 2014.
- Cash Position: Cash and equivalents constituted 20.5% of total assets in 2025, down from 21.8% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 72.0% of total assets, a decrease from 75.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 55.7% of total assets.
Mesoblast Limited Competitors by Total Assets
Key competitors of Mesoblast Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Mesoblast Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.58 | 0.96 | 0.99 |
| Quick Ratio | 1.41 | 0.63 | 0.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €74.41 Million | €-3.07 Million | €-582.00K |
Mesoblast Limited - Advanced Valuation Insights
This section examines the relationship between Mesoblast Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.15 |
| Latest Market Cap to Assets Ratio | 1.99 |
| Asset Growth Rate (YoY) | 17.3% |
| Total Assets | €784.68 Million |
| Market Capitalization | $1.56 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Mesoblast Limited's assets above their book value (1.99x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Mesoblast Limited's assets grew by 17.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Mesoblast Limited (2014–2025)
The table below shows the annual total assets of Mesoblast Limited from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | €784.68 Million ≈ $917.38 Million |
+17.27% |
| 2024-06-30 | €669.15 Million ≈ $782.31 Million |
-0.04% |
| 2023-06-30 | €669.41 Million ≈ $782.62 Million |
+1.10% |
| 2022-06-30 | €662.14 Million ≈ $774.11 Million |
-11.09% |
| 2021-06-30 | €744.72 Million ≈ $870.65 Million |
+1.52% |
| 2020-06-30 | €733.60 Million ≈ $857.66 Million |
+12.50% |
| 2019-06-30 | €652.12 Million ≈ $762.39 Million |
-5.82% |
| 2018-06-30 | €692.44 Million ≈ $809.54 Million |
+5.61% |
| 2017-06-30 | €655.69 Million ≈ $766.57 Million |
-4.14% |
| 2016-06-30 | €684.02 Million ≈ $799.69 Million |
-12.50% |
| 2015-06-30 | €781.77 Million ≈ $913.97 Million |
-7.82% |
| 2014-06-30 | €848.13 Million ≈ $991.55 Million |
-- |
About Mesoblast Limited
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic… Read more